Skip to main content

Conference Highlights ASH

Transplant for Mantle-Cell Lymphoma: Is it the Right Thing to Do?

Combination Biologic Therapy Without Chemotherapy as Initial Treatment for Mantle-Cell Lymphoma: Multicenter Phase 2 Study of Lenalidomide Plus Rituximab

Phase 2 Trial of GS-9973, a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia

Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed or Refractory CLL/SLL: Final Results of a Phase 1b Study

Ibrutinib in Combination with Rituximab is Well Tolerated and Induces a High Rate of Durable Remissions in Patients with High-Risk Chronic Lymphocytic Leukemia: New, Updated Results of a Phase 2 Trial in 40 Patients

Single-Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses in Patients with Chronic Lymphocytic Leukemia with and without Deletion 17p

A Multicenter, Phase 4 Observational Study of Ofatumumab in Chronic Lymphocytic Leukemia: A European Research Initiative on CLL (ERIC) Study

The Bruton’s Tyrosine Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability of Response in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in an Open-Label Extension Study

Ofatumumab + Chlorambucil versus Chlorambucil Alone in Patients with Untreated Chronic Lymphocytic Leukemia: Results of the Phase 3 Study Complement 1 (OMB110911)

1
2
3
4

Page 2 of 4
Results 11 - 20 of 35